参考文献/References:
[1] Islam MS,Wang C,Zheng J,et al.The potential role of tubeimosides in cancer prevention and treatment[J].Eur J Med Chem,2019(162):109-121.
[2] 裴晓华,彭艳梅.中医药治疗恶性肿瘤70年[J].中国肿瘤外科杂志,2019,11(5):305-308.
[3] 朱晓丹,安 超,姜 敏,等.从文献角度探索中药土贝母药用源流[J].环球中医药,2018,11(6):884-886.
[4] Erridge SC,Moller H,Price A,et al.International comparisons of survival from lung cancer:Pitfalls and warnings[J].Nat Clin Pract Oncol,2007,4(10):570-577.
[5] Zhang Y,Xu X,He P.Tubeimoside-1 inhibits proliferation and induces apoptosis by increasing the Bax to Bcl-2 ratio and decreasing COX-2 expression in lung cancer A549 cells[J].Mol Med Rep,2011,4(1):25-29.
[6] 苏甲林,赵参军,郑 瑾.土贝母苷甲对人肺腺癌细胞增殖及凋亡的影响[J].临床肺科杂志,2021,26(1):95-100.
[7] Hao W,Wang S,Zhou Z.Tubeimoside-1(TBMSⅠ)inhibits lung cancer cell growth and induces cells apoptosis through activation of MAPK-JNK pathway[J].Int J Clin Exp Pathol,2015,8(10):12075-12083.
[8] Lin Y,Xie G,Xia J,et al.TBMSⅠ exerts its cytotoxicity in NCI-H460 lung cancer cells through nucleolar stress-induced p53/MDM2-dependent mechanism,a quantitative proteomics study[J].Biochim Biophys Acta,2016,1864(2):204-210.
[9] Poillet PL,White E.Role of tumor and host autophagy in cancer metabolism[J].Genes Dev,2019,33(11):610-619.
[10] Wang K,Zhan Y,Chen B,et al.Tubeimoside I-induced lung cancer cell death and the underlying crosstalk between lysosomes and mitochondria[J].Cell Death Dis,2020,11(8):708.
[11] Gu Y,Korbel C,Scheuer C,et al.Tubeimoside-1 suppresses tumor angiogenesis by stimulation of proteasomal VEGFR2 and Tie2 degradation in a non-small cell lung cancer xenograft model[J].Oncotarget,2016,7(5):5258-5272.
[12] Shi H,Bi H,Sun X,et al.Tubeimoside-1 inhibits the proliferation and metastasis by promoting miR-126-5p expression in non-small cell lung cancer cells[J].Oncol Lett,2018,16(3):3126-3134.
[13] 王欣悦,朱雪婷,刘天赋,等.土贝母皂苷甲逆转A549/DDP细胞系耐药性的分子效应[J].基因组学与应用生物学,2020,39(8):3600-3606.
[14] Chan JY.Surgical salvage of recurrent nasopharyngeal carcinoma[J].Curr Oncol Rep,2015,17(3):433.
[15] Ma R,Song G,You W,et al.Anti-microtubule activity of tubeimoside I and its colchicine binding site of tubulin[J].Cancer Chemother Pharmacol,2008,62(4):559-568.
[16] 翁昔阳,马润娣,于立坚.土贝母苷甲诱导人鼻咽癌细胞CNE-2Z凋亡[J].癌症,2003,22(8):806-811.
[17] 刘姬艳,马润娣,于立坚.土贝母苷甲对人鼻咽癌上皮细胞丝裂原活化蛋白激酶活性的影响[J].北京中医,2007,27(2):119-121.
[18] Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[19] Wang Y,Deng L,Zhong H,et al.Natural plant extract tubeimoside I promotes apoptosis-mediated cell death in cultured human hepatoma(HepG2)cells[J].Biol Pharm Bull,2011,34(6):831-838.
[20] Peter ME,Krammer PH.The CD95(APO-1/Fas)DISC and beyond[J].Cell Death Differ,2003,10(1):26-35.
[21] Yin Y,Chen W,Tang C,et al.NF-kappaB,JNK and p53 pathways are involved in tubeimoside-1-induced apoptosis in HepG2 cells with oxidative stress and G2/M cell cycle arrest[J].Food Chem Toxicol,2011,49(12):3046-3054.
[22] Cheng J,Zhang T,Ji H,et al.Functional characterization of AMP-activated protein kinase signaling in tumorigenesis[J].Biochim Biophys Acta,2016,1866(2):232-251.
[23] Kabeya Y,Mizushima N,Ueno T,et al.LC3,a mammalian homologue of yeast Apg8p,is localized in autophagosome membranes after processing[J].The EMBO Journa,2000,19(21):5720-5728.
相似文献/References:
[1]黄越秀,陈光伟,张家墉△,等.陈光伟教授治疗肿瘤根治术后肠麻痹经验[J].陕西中医,2020,(11):1654.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.036]
[2]曾普华.从炎性微环境探析肿瘤恶液质的“癌毒致虚”病机观[J].陕西中医,2021,(8):987.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.001]
ZENG Puhua.Analysis of the “cancer toxin-induced deficiency” pathogenesis of tumor cachexia from the inflammatory microenvironment[J].,2021,(11):987.[doi:DOI:10.3969/j.issn.1000-7369.2020.08.001]
[3]张小力,刘 芹,刘宝瑞.重楼皂苷抗肿瘤及调节肿瘤免疫微环境研究进展[J].陕西中医,2021,(11):1640.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.033]
ZHANG Xiaoli,LIU Qin,LIU Baorui.Advances in anti-tumor effects of paris saponins[J].,2021,(11):1640.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.033]
[4]张美英,张 英,侯 炜.基于数据挖掘探讨黄芪抗肿瘤复方的临床应用[J].陕西中医,2023,(7):957.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.031]
[5]冯薪宇,罗富锟,胡利来,等.肿瘤中医病机发展与“辨病识机”指导意义[J].陕西中医,2025,46(2):237.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.019]
FENG Xinyu,LUO Fukun,HU Lilai,et al.The innovative development of TCM tumor pathogenesis and the guiding significance of “disease identification machine”[J].,2025,46(11):237.[doi:DOI:10.3969/j.issn.1000-7369.2025.02.019]